Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

10.1186/1471-2407-14-592

Saved in:
Bibliographic Details
Main Authors: Haaland, B, Chopra, A, Acharyya, S, Fay, A.P, Lopes, G.L
Other Authors: DUKE-NUS MEDICAL SCHOOL
Format: Article
Published: 2020
Subjects:
Online Access:https://scholarbank.nus.edu.sg/handle/10635/181520
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
id sg-nus-scholar.10635-181520
record_format dspace
spelling sg-nus-scholar.10635-1815202023-11-01T07:42:40Z Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma Haaland, B Chopra, A Acharyya, S Fay, A.P Lopes, G.L DUKE-NUS MEDICAL SCHOOL bevacizumab interferon pazopanib sunitinib angiogenesis inhibitor antineoplastic agent bevacizumab indole derivative interferon monoclonal antibody pazopanib pyrimidine derivative pyrrole derivative sulfonamide sunitinib anemia anorexia Article asthenia cancer risk comparative study diarrhea drug efficacy drug safety drug withdrawal dyspnea fatigue fever headache human hypertension kidney carcinoma loss of appetite metastatic clear cell renal cell carcinoma metastatic clear cell renal cell carcinoma nausea neutropenia overall survival progression free survival proteinuria randomized controlled trial (topic) side effect systematic review thrombocytopenia thyroid disease treatment outcome treatment response Carcinoma, Renal Cell Kidney Neoplasms meta analysis molecularly targeted therapy Neoplasm Metastasis survival Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Carcinoma, Renal Cell Humans Indoles Interferons Kidney Neoplasms Molecular Targeted Therapy Neoplasm Metastasis Pyrimidines Pyrroles Randomized Controlled Trials as Topic Sulfonamides Survival Analysis 10.1186/1471-2407-14-592 BMC Cancer 14 1 592 2020-10-27T11:11:13Z 2020-10-27T11:11:13Z 2014 Article Haaland, B, Chopra, A, Acharyya, S, Fay, A.P, Lopes, G.L (2014). Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma. BMC Cancer 14 (1) : 592. ScholarBank@NUS Repository. https://doi.org/10.1186/1471-2407-14-592 14712407 https://scholarbank.nus.edu.sg/handle/10635/181520 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution National University of Singapore
building NUS Library
continent Asia
country Singapore
Singapore
content_provider NUS Library
collection ScholarBank@NUS
topic bevacizumab
interferon
pazopanib
sunitinib
angiogenesis inhibitor
antineoplastic agent
bevacizumab
indole derivative
interferon
monoclonal antibody
pazopanib
pyrimidine derivative
pyrrole derivative
sulfonamide
sunitinib
anemia
anorexia
Article
asthenia
cancer risk
comparative study
diarrhea
drug efficacy
drug safety
drug withdrawal
dyspnea
fatigue
fever
headache
human
hypertension
kidney carcinoma
loss of appetite
metastatic clear cell renal cell carcinoma
metastatic clear cell renal cell carcinoma
nausea
neutropenia
overall survival
progression free survival
proteinuria
randomized controlled trial (topic)
side effect
systematic review
thrombocytopenia
thyroid disease
treatment outcome
treatment response
Carcinoma, Renal Cell
Kidney Neoplasms
meta analysis
molecularly targeted therapy
Neoplasm Metastasis
survival
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
Humans
Indoles
Interferons
Kidney Neoplasms
Molecular Targeted Therapy
Neoplasm Metastasis
Pyrimidines
Pyrroles
Randomized Controlled Trials as Topic
Sulfonamides
Survival Analysis
spellingShingle bevacizumab
interferon
pazopanib
sunitinib
angiogenesis inhibitor
antineoplastic agent
bevacizumab
indole derivative
interferon
monoclonal antibody
pazopanib
pyrimidine derivative
pyrrole derivative
sulfonamide
sunitinib
anemia
anorexia
Article
asthenia
cancer risk
comparative study
diarrhea
drug efficacy
drug safety
drug withdrawal
dyspnea
fatigue
fever
headache
human
hypertension
kidney carcinoma
loss of appetite
metastatic clear cell renal cell carcinoma
metastatic clear cell renal cell carcinoma
nausea
neutropenia
overall survival
progression free survival
proteinuria
randomized controlled trial (topic)
side effect
systematic review
thrombocytopenia
thyroid disease
treatment outcome
treatment response
Carcinoma, Renal Cell
Kidney Neoplasms
meta analysis
molecularly targeted therapy
Neoplasm Metastasis
survival
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
Humans
Indoles
Interferons
Kidney Neoplasms
Molecular Targeted Therapy
Neoplasm Metastasis
Pyrimidines
Pyrroles
Randomized Controlled Trials as Topic
Sulfonamides
Survival Analysis
Haaland, B
Chopra, A
Acharyya, S
Fay, A.P
Lopes, G.L
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
description 10.1186/1471-2407-14-592
author2 DUKE-NUS MEDICAL SCHOOL
author_facet DUKE-NUS MEDICAL SCHOOL
Haaland, B
Chopra, A
Acharyya, S
Fay, A.P
Lopes, G.L
format Article
author Haaland, B
Chopra, A
Acharyya, S
Fay, A.P
Lopes, G.L
author_sort Haaland, B
title Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
title_short Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
title_full Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
title_fullStr Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
title_full_unstemmed Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
title_sort comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
publishDate 2020
url https://scholarbank.nus.edu.sg/handle/10635/181520
_version_ 1781792535233953792